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Abstract 
Background: Uromodulin is specifically synthesized and secreted by kidney tubular epithelial cells. Studies on the 
association of serum uromodulin and outcomes of chronic kidney disease (CKD) are lacking. This study aimed to 
evaluate whether serum uromodulin was associated with outcomes of patients with CKD.
Methods: We measured serum uromodulin concentrations by ELISA in 2652 CKD patients from the Chinese Cohort 
Study of Chronic Kidney Disease (C‑STRIDE) and investigated the association of serum uromodulin with outcomes of 
CKD patients, including end‑stage kidney disease (ESKD) receiving kidney replacement therapy, cardiovascular events 
and mortality by Cox proportional hazards regression model.
Results: A total of 2652 CKD patients were enrolled in this study, with an age of 48.7 ± 13.8 years and the baseline 
eGFR of 49.6 ± 29.4 mL/min/1.73 m2, of whom 58.4% were male. The median level of urinary albumin/creatinine ratio 
and serum uromodulin was 473.7 mg/g (IQR 134.1–1046.6 mg/g) and 77.2 ng/mL (IQR 48.3–125.9 ng/mL), respec‑
tively. Altogether, 404 ESKD, 189 cardiovascular events, and 69 deaths occurred during the median follow‑up of 53.6 
(IQR 44.0–64.0) months. Lower levels of serum uromodulin were independently associated with higher risk of incident 
ESKD after adjusting for traditional cardiovascular risk factors, with the hazard ratios (HRs) of 3.23 (95% confidence 
intervals [CIs] 2.15–4.85) for the middle tertile and 7.47 (95% CI 5.06–11.03) for the bottom tertile, compared with top 
tertile and 0.31 (95% CI 0.25–0.38) per every standard deviation increase. After further adjustment for the baseline 
eGFR, the association was greatly attenuated, but still significant, with HRs of 1.92 (95% CI 1.26–2.90) for the bottom 
tertile compared with top tertile and 0.69 (95% CI 0.55–0.86) per every standard deviation increase.
Conclusions: Serum uromodulin is independently associated with an increased risk of incident ESKD in CKD patients.
Keywords: Uromodulin, Chronic kidney disease, Outcomes
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic kidney disease (CKD), with a high prevalence of 
over 10%, is one of the leading global public health prob-
lems [1]. In addition to progression to end-stage kidney 
disease (ESKD), patients with CKD are at high risk for 
cardiovascular disease and mortality [2]. It is thus par-
ticularly important to distinguish high-risk CKD patients. 
To date, biomarkers for evaluating the risk of CKD pro-
gression are restricted to the estimated glomerular fil-
tration rate (eGFR) and proteinuria; these cannot fully 
reflect the tubulointerstitial function or the heterogene-
ity of CKD progression. Based on some previous studies, 
tubulointerstitial lesions might be more important for 
predicting kidney disease progression than glomerular 
and vascular lesions in patients with various kidney dis-
eases [3–6]. The status of tubulointerstitium might better 
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reflect total nephron mass and therefore could be help-
ful for identifying high-risk CKD patients more precisely. 
However, such kinds of markers are not well-established.
Uromodulin is the most abundant protein in urine 
[7–9] and is specifically synthesized and secreted by kid-
ney tubular epithelial cells. Rare mutations in the UMOD 
gene have been described as a cause of hereditary auto-
somal-dominant tubulointerstitial diseases [10, 11]. Well-
known genome-wide association studies (GWAS) have 
successfully identified common variants in the UMOD 
gene as risk factors for CKD and hypertension in the 
general population [12–14]. Recently, some prospective 
studies showed that serum uromodulin levels were inde-
pendently associated with the risk of cardiovascular event 
and mortality as well as decline in kidney function among 
patients referred to angiography [15–17]. It is not yet 
known whether serum uromodulin was associated with 
outcomes of CKD patients. Hence, in the current study, 
we measured the serum uromodulin levels and investi-
gated the association of serum uromodulin with kidney 
function and outcomes of CKD in a large, multicenter 
prospective cohort study of CKD patients, the Chinese 
Cohort Study of Chronic Kidney Disease (C-STRIDE).
Methods
Participants
The C-STRIDE is a multicenter prospective cohort of 
CKD patients, containing 39 clinical centers in different 
geographic regions of China. The criteria for the enroll-
ment of participants are listed in Additional file 1. CKD 
participants have been enrolled from November 2011, a 
total of 3499 patients have completed screening until 30 
June 2016, of which 686 patients were excluded due to 
missing values of serum creatinine and/or loss of follow-
up data, altogether 2813 patients have the completed 
baseline and follow-up data. Due to the availability of 
the biosamples for measuring serum uromodulin, there-
fore, 2652 patients were included in the present study. 
For the etiologic diagnosis, there were 1707 patients with 
glomerular diseases, 547 patients with tubulointerstitial 
diseases and 398 patients with other or unknown causes. 
The design of C-STRIDE has been described elsewhere in 
detail [18].
Study design
We measured serum uromodulin levels of 2652 CKD 
patients at baseline and described the distribution of 
baseline data of these patients according to serum uro-
modulin levels. Then, we further investigated the associa-
tions of serum uromodulin with pre-specified end-points 
of CKD patients, including ESKD, cardiovascular events 
and all-cause mortality. The baseline data included 
detailed demographics, underlying disease, behavioral 
habits, medical and medication history, anthropometric 
measures (height, weight, resting blood pressure), chem-
istry indexes (triglyceride, total cholesterol, low-density 
lipoprotein cholesterol, high-density lipoprotein cho-
lesterol, fasting blood glucose, prealbumin, serum cre-
atinine, high-sensitivity C-reactive protein), and urinary 
albumin/creatinine ratio. The end-point events of CKD 
patients were collected before 30 June 2017. All these 
patients gave written informed consent before data col-
lection. The study was approved by the Ethics Committee 
of Peking University First Hospital and was in adherence 
with the Declaration of Helsinki.
Detection of serum uromodulin by enzyme‑linked 
immunosorbent assay (ELISA)
Fasting venous blood samples were obtained at the study 
visit. All participants’ blood samples were transported by 
cold chain to the Central Laboratory of Peking Univer-
sity First Hospital and stored at − 80 °C until use. Serum 
uromodulin was measured in batches from stored mate-
rial in the Central Laboratory of Peking University First 
Hospital from May 2016 to August 2016. We measured 
serum uromodulin by a commercially available ELISA 
kit (Euroimmun AG, Lübeck, Germany) according to the 
manufacturer’s instructions. The process of the assay was 
described in Additional file 1.
Measurement of covariates
The covariates in the multivariable models were either 
potential confounders, or the independent predictors 
of the adverse outcomes. All blood and urine samples 
were analyzed in the Central Laboratory of Peking Uni-
versity First Hospital to avoid the variation of testing 
values between laboratories. Serum total, low-density 
lipoprotein, and high-density lipoprotein cholesterol, tri-
glycerides were measured with commercially available 
reagents. Urinary albumin and creatinine were measured 
from a fresh morning spot urine sample or morning urine 
sample stored at 4 °C for less than 1 week. Albuminuria 
was measured with immunoturbidimetric tests. Urinary 
creatinine was measured with the ammonia iminohy-
drolase method. The urinary albumin to creatinine ratio 
(mg/g creatinine) was calculated. Serum creatinine was 
measured by the same methods as urinary creatinine. 
The eGFR was evaluated by the equation developed by 
adaptation of the Modification of Diet in Renal Disease 
(MDRD) equation on the basis of data from the Chinese 
CKD participants: eGFR = 175 × (serum creatinine [in 
μmol/L]/88.4)−1.234 × age−0.179 × (if female × 0.79) [19]. 
All eGFR values of more than 120 mL/min/1.73 m2 were 
set at 120 mL/min/1.73 m2.
Body mass index was calculated by using the follow-
ing formula: weight (kg)/height2  (m2). Blood pressure 
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was measured three times at 5-min intervals by a sphyg-
momanometer. The mean value of the three readings 
was calculated. The use of anti-hypertensive medica-
tions in the past 2 weeks before baseline examination was 
recorded. Diabetes was defined as the fasting plasma glu-
cose of 7.0 mmol/L or more, or the use of hypoglycemic 
agents or a self-reported history of diabetes.
Study outcomes
The pre-specified end-point events of the CKD patients 
included ESKD, cardiovascular event, and all-cause mor-
tality. ESKD is defined as the initiation of chronic dialysis 
or renal kidney transplantation or irreversible develop-
ment of eGFR < 15 mL/min/1.73 m2. All the ESKD events 
included in the current study have initiated hemodialy-
sis, or peritoneal dialysis, or kidney transplantation. Car-
diovascular events included acute myocardial infarction, 
unstable angina, hospitalization for congestive heart 
failure, cerebrovascular events (intraparenchymal hem-
orrhage, subarachnoid hemorrhage, cerebral infarction, 
etc.), and peripheral vascular diseases. Echocardiogram 
and electrocardiogram examination were requested in 
the validation of cardiovascular events; however, cardio-
angiography was not routinely performed. Only one 
event per patient was included in the current analysis. 
Finally, we separately evaluated the associations of base-
line serum uromodulin with different clinical outcomes 
of CKD patients, including ESKD, cardiovascular events 
and all-cause mortality.
The end-point events were collected at 3- to 6-month 
intervals until 30 June 2017 in the current analysis. 
The director at each clinical center asked for end-point 
events according to the new-onset events registration 
form either by phone calls or routine clinical visits. Once 
the end-point events occurred, the director at the clini-
cal center filled out the new-onset events registration 
form and submitted the related clinical data to the Renal 
Institute of Peking University via email within 1 month. 
The suspected clinical outcomes were then adjudicated 
by an independent committee consisting of specialist 
physicians.
Statistical analysis
All CKD patients were stratified according to tertiles 
of baseline serum uromodulin levels. Continuous vari-
ables are presented as the means and standard devia-
tions, except for highly skewed variables that are shown 
as median and interquartile ranges (IQR), and categori-
cal variables are presented as proportions. One-way 
ANOVA was used to compare continuous variables, 
and Chi squared tests were used to compare categorical 
variables.
The incidence rates of end-point events (including 
ESKD, cardiovascular event and all-cause mortality) were 
calculated as number of events per 100 person-years. We 
depicted cumulative hazard function for the three events 
separately according to uromodulin levels by using a 
Kaplan–Meier curve and compared the event rates by 
using log-rank test.
To investigate the association between serum uromod-
ulin and outcomes, Cox proportional hazards regression 
models were used to estimate hazards ratios (HRs) and 
95% confidence intervals (CIs). We found that the risk 
of ESKD was linearly increased through the decline of 
uromodulin as shown in the linear spline analysis (Addi-
tional file 1: Figure S1), so we treated uromodulin either 
as a categorical variable (using the highest tertile as the 
reference) or a continuous variable (per standard devia-
tion change) to represent the exposure variable. Multi-
variable models were constructed to adjust for potential 
confounding variables of the adverse outcomes, including 
age (continuous), gender (male vs. female), body-mass 
index (continuous), current smoker (yes vs. no), previ-
ous history of cardiovascular disease (yes vs. no), systolic 
blood pressure (continuous), using anti-hypertensive 
medications in the past 2  weeks (yes vs. no), diabetes 
(yes vs. no), prealbumin (continuous), logarithm trans-
formed low-density lipoprotein cholesterol, high-density 
lipoprotein cholesterol [20], triglyceride, high-sensitivity 
C-reactive protein, urinary albumin/creatinine ratio (all 
in continuous), and eGFR (continuous). The missing val-
ues were filled before they were entered in the regres-
sion model. The proportional hazards assumption was 
assessed via Kaplan–Meier curves using log–log plots. 
We fitted logistic regression model by using the same 
covariates in the Cox regression model and calculated 
area under receiver operating characteristic curve (AUC). 
We compared AUCs inclusion or exclusion of serum uro-
modulin in the model with traditional cardiovascular risk 
factors, eGFR and ACR, in order to evaluate the change 
in discriminating ability for ESKD after inclusion of 
serum uromodulin. Statistical analyses were performed 
using the SAS software (version 9.4, SAS institute, CA, 
USA). P < 0.05 (two-sided) was considered statistically 
significant.
Results
Baseline characteristics by serum uromodulin levels
Among the 2652 CKD patients included in our study, 
1548 (58.4%) were male, and 1104 (41.6%) were female, 
with an age of 48.7 ± 13.8 years. The baseline eGFR was 
49.6 ± 29.4 mL/min/1.73 m2. A total of 788 (29.7%) par-
ticipants had an eGFR greater than 60 mL/min/1.73 m2 
at baseline. Altogether, 1053 (39.7%) and 811 (30.6%) 
patients were in CKD stages 3 and 4, respectively.
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The median level of serum uromodulin was 77.2 ng/mL 
(IQR 48.3–125.9 ng/mL) in 2652 CKD patients. The levels 
in the three etiologic types of CKD were 100.4 ± 65.6 ng/
mL in glomerular diseases, 69.0 ± 40.6  ng/mL in tubu-
lointerstitial diseases and 73.4 ± 51.4  ng/mL in other or 
unknown causes, respectively (P < 0.001). The baseline 
characteristics of CKD patients according to tertiles of 
the serum uromodulin levels are presented in Table  1. 
Compared with patients with higher serum uromodulin 
levels, those with lower uromodulin levels were older, 
had a higher proportion of previous history of smoking, 
diabetes, and cardiovascular disease, higher proportion 
of current use of antihypertensive medications, and had 
higher levels of blood pressure, triglyceride, high-sensi-
tivity C-reactive protein and urinary albumin/creatinine 
ratio but lower levels of total cholesterol and eGFR. The 
patients with missing value in the clinical characteristics 
tended to have a lower uromodulin level in our study. For 
example, the uromodulin levels were 79.20  ng/mL and 
92.19  ng/mL, respectively, among those with and with-
out missing value of systolic blood pressure (P < 0.001). In 
addition, we found a positive correlation between serum 
uromodulin and eGFR in multivariable linear correlation 
analysis (r = 0.68, P < 0.001).
The incidence rates of the end‑point events according 
to levels of serum uromodulin
The incidence rates of end-point events according to lev-
els of serum uromodulin are shown in Table  2. During 
the median follow-up of 53.6 (IQR 44.0–64.0) months, 
there were 404 ESKD, 189 cardiovascular events and 69 
deaths occurred. ESKD, cardiovascular events and death 
rates were 3.60, 1.60 and 0.57 per 100 person-years, 
respectively. Higher incidence rates of all the three end-
point events were seen with the decreased levels of uro-
modulin (Figs. 1, 2, 3, all P-values for log-rank test < 0.05).
Table 1 Baseline characteristics of the patients by tertiles of serum uromodulin
Missing counts: body mass index: 396, systolic blood pressure: 492, diastolic blood pressure: 492, smoking status: 271, diabetes: 16, using anti-hypertensive 
medications in the past 2 weeks: 619, cardiovascular disease: 240, triglyceride: 64, total cholesterol: 68, high-density lipoprotein cholesterol: 80, low-density 
lipoprotein cholesterol: 81, fasting blood glucose: 96, prealbumin: 151, high sensitive-reactive protein: 606, urinary albumin/creatinine ratio: 299
Characteristics Total (N = 2652) Serum uromodulin tertiles (ng/mL)
≤ 52.7 (N = 885) > 52.7–100.8 (N = 881) > 100.8 (N = 886)
Age (years) 48.7 ± 13.8 50.2 ± 13.6 50.0 ± 13.2 45.9 ± 14.1
Male (n%) 1548 (58.4%) 513 (58.0%) 534 (60.6%) 501 (56.6%)
Body mass index (kg/m2) 24.4 ± 3.6 24.2 ± 3.7 24.7 ± 3.7 24.4 ± 3.5
Systolic blood pressure (mmHg) 130.1 ± 19.3 135.7 ± 20.5 130.4 ± 18.4 124.7 ± 17.7
Diastolic blood pressure (mmHg) 81.3 ± 11.7 83.6 ± 12.4 81.6 ± 11.7 78.8 ± 10.4
Smoking status (n%) 907 (38.1%) 325 (42.4%) 300 (38.2%) 282 (34.0%)
Diabetes (n%) 516 (19.6%) 178 (20.3%) 202 (23.1%) 136 (15.4%)
Using anti‑hypertensive medications in the past 2 weeks 
(n%)
1488 (73.2%) 540 (82.3%) 524 (76.7%) 424 (61.1%)
Cardiovascular disease (n%) 293 (12.2%) 121 (15.6%) 114 (14.2%) 58 (7.0%)
Triglyceride (mmol/L) 1.8 (1.3, 2.6) 1.8 (1.3, 2.6) 1.8 (1.3, 2.7) 1.7 (1.2, 2.4)
Total cholesterol (mmol/L) 4.8 (4.0, 5.8) 4.5 (3.7, 5.4) 4.9 (4.1, 5.9) 5.0 (4.1, 6.2)
High‑density lipoprotein cholesterol (mmol/L) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 1.1 (0.9, 1.3) 1.2 (1.0, 1.4)
Low‑density lipoprotein cholesterol (mmol/L) 2.6 (2.1, 3.3) 2.4 (2.0, 3.0) 2.6 (2.1, 3.3) 2.8 (2.2, 3.5)
Fasting blood glucose (mmol/L) 4.9 (4.4, 5.6) 4.9 (4.4, 5.6) 5.0 (4.4, 5.7) 4.9 (4.4, 5.5)
Prealbumin (g/L) 326.5 ± 83.1 348.7 ± 87.6 327.6 ± 79.3 303.2 ± 75.6
High sensitive–reactive protein (mg/L) 1.3 (0.5, 3.0) 1.5 (0.6, 3.6) 1.4 (0.6, 3.1) 1.0 (0.4, 2.5)
Urinary albumin/creatinine ratio (mg/g) 473.7 (134.1, 1046.6) 661.7 (233.9, 1352.8) 439.9 (113.2, 969.9) 374.3 (100.0, 836.6)
Creatinine (μmol/L) 173.8 ± 121.8 247.4 ± 138.6 165.7 ± 114.5 108.4 ± 49.1
Estimated glomerular filtration rate (mL/min/1.73 m2) 49.6 ± 29.4 28.5 ± 15.0 46.3 ± 23.0 74.0 ± 28.0
Estimated glomerular filtration rate group (mL/min/1.73 m2)
 ≥ 90 337 (12.7%) 5 (0.6%) 58 (6.6%) 274 (30.9%)
 60–89 451 (17.0%) 31 (3.5%) 111 (12.6%) 309 (34.9%)
 45–59 419 (15.8%) 73 (8.3%) 211 (24.0%) 135 (15.2%)
 30–44 634 (23.9%) 211 (23.8%) 297 (33.7%) 126 (14.2%)
 15–29 811 (30.6%) 565 (63.8%) 204 (23.2%) 42 (4.7%)
Page 5 of 9Lv et al. J Transl Med          (2018) 16:316 
Associations of serum uromodulin with ESKD, 
cardiovascular events and all‑cause mortality
The association of serum uromodulin with outcomes is 
shown in  Table  3. After adjusting for demographic and 
traditional cardiovascular risk factors, as well as the 
baseline eGFR levels, baseline serum uromodulin levels 
were independently associated with the risk of incident 
ESKD, with an HR of 1.92 (95% CI 1.26–2.90) in the bot-
tom tertile compared with the top tertile. Every standard 
deviation increase of uromodulin was associated with a 
decreased risk of ESKD, with an HR of 0.69 (95% CI 0.55–
0.86). However, we did not detect significant associations 
between serum uromodulin and the risk of cardiovascu-
lar events as well as all-cause mortality in multivariable 
adjusted model. Similar results were found among sub-
group of patients with glomerular diseases and tubuloint-
erstitial diseases (Additional file 1: Tables S1, S2).
In the fully adjusted logistic regression model for 
ESKD, the AUCs with inclusion or exclusion of serum 
uromodulin level were 0.8623 (95% CI 0.8438–0.8808) 
and 0.8601 (95% CI 0.8413–0.8789), respectively. The 
difference of the AUCs was 0.0023 (95% CI − 0.0007 to 
0.0052) (P-value for the difference = 0.1).
Table 2 Association between  the  uromodulin levels 
and the end-point events rates
Serum 
uromodulin 
tertiles (ng/mL)
Number 
of events
Events 
per 100 
person‑years
P for log‑rank
ESRD events < 0.001
 ≤ 52.7 (N = 885) 267 (30.17%) 7.86
 > 52.7–100.8 
(N = 881)
106 (12.03%) 2.80
 > 100.8 (N = 886) 31 (3.50%) 0.77
Total 404 (15.23%) 3.60
Cardiovascular events < 0.001
 ≤ 52.7 (N = 885) 86 (9.72%) 2.20
 > 52.7–100.8 
(N = 881)
63 (7.15%) 1.62
 > 100.8 (N = 886) 40 (4.51%) 0.99
Total 189 (7.13%) 1.60
All‑cause mortality 0.003
 ≤ 52.7 (N = 885) 35 (3.95%) 0.87
 > 52.7–100.8 
(N = 881)
22 (2.50%) 0.55
 > 100.8 (N = 886) 12 (1.35%) 0.29
Total 69 (2.60%) 0.57
Fig. 1 Kaplan–Meier curve for ESKD events according to tertiles of serum uromodulin
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Fig. 2 Kaplan–Meier curve for cardiovascular events according to tertiles of serum uromodulin
Fig. 3 Kaplan–Meier curve for all‑cause mortality according to tertiles of serum uromodulin
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Discussion
In the current study, we described the association of 
serum uromodulin and ESKD, cardiovascular events, 
all-cause mortality in the context of CKD. We found 
that the baseline lower levels of serum uromodu-
lin were associated with an increased risk of incident 
ESKD independent of the traditional risk factors for 
progression of CKD.
Uromodulin is a glycosyl phosphatidylinositol (GPI) 
linked glycoprotein exclusively synthesized in renal tubu-
lar epithelial cells [21]. Most of the uromodulin protein 
cleaved by proteolysis is released into the urine [22, 
23]; a smaller but significant basolateral release of uro-
modulin is secreted to the tubulointerstitium [3, 24–26] 
and is detected in the blood. Recently, two SNPs within 
the promoter region of the UMOD gene were found to 
be associated with a decline in the occurrence of CKD 
and a lower urinary uromodulin level [12, 13]. Previous 
studies mainly focused on urinary uromodulin excretion 
[8, 25, 27], but serum uromodulin has not been investi-
gated widely. Furthermore, serum uromodulin is a stable 
monomeric antigen and seem to be more reliably meas-
ured [28]. Thus, we evaluated whether the level of serum 
uromodulin was associated with outcomes of CKD in 
a large, multicenter prospective cohort study of CKD 
patients.
To the best of our knowledge, the current study is the 
first prospective one assessing the association between 
serum uromodulin and kidney disease progression in 
CKD population. Our results were, to some extent, in 
line with several recent studies [17, 29]. A recent cross-
sectional study by Steubl et  al. presented that plasma 
uromodulin could identify early stages of CKD [29]. 
Additionally, Leiherer et al. [17] reported that lower lev-
els of serum uromodulin were independently associated 
with the decline of kidney function and the incidence 
of CKD in patients with established or suspected sta-
ble coronary artery disease. However, most of partici-
pants included in their study had normal and moderately 
reduced kidney function and failed to reach the endpoint 
of ESKD during follow-up. Thus, we extended the pre-
vious observation by a large, prospective Chinese CKD 
cohort with a broad range of eGFR.
Uromodulin is specifically secreted by renal tubu-
lar epithelial cells. Experimental data from Trudu [14] 
showed that over-expression of uromodulin leads to 
salt-sensitive hypertension, left ventricular hypertrophy 
and kidney damage. SNPs leading to overexpression of 
uromodulin in humans are strongly associated with a 
greater risk of CKD [13]. The above situation is based on 
individuals with physically functional kidney and varia-
tion of uromodulin exits due to the genetic background 
among individuals. However, in the setting of abnormal 
kidney function/kidney damage, the decline in absolute 
uromodulin excretion was caused by the reduction in 
functional nephron mass and/or reserve of the tubules 
[11, 30]. It is possible that a decline in urinary uromod-
ulin excretion from apical secretion is associated with a 
decline in basolateral release, as evidenced by a decline 
in the level of serum uromodulin in CKD patients [31, 
32]. Thus, lower levels of serum uromodulin indirectly 
reflected abnormalities in renal tubulointerstitial func-
tion, which is associated with a reduction in erythropoi-
etin production, acid–base homeostasis disequilibrium 
and mineral metabolism disorder, which therefore links 
the rapid progress on kidney function.
Although the physiological role of circulating uro-
modulin remains largely unknown, the present data 
strengthens the notion that serum uromodulin repre-
sents a marker of kidney health independent of markers 
of the glomerular function and might help to distinguish 
high-risk CKD patients with rapid progress on kidney 
function. With regard to the ESKD events, our results 
only found a trend of improvement in the discriminat-
ing ability after inclusion of serum uromodulin in the 
model with traditional markers for kidney function and 
Table 3 Association of  serum uromodulin with  ESKD, 
cardiovascular events and all-cause mortality
Model 1: Adjusted for age, gender
Model 2: Model 1+ current smoker, body-mass index, diabetes, systolic 
blood pressure, using anti-hypertensive medications in the past 2 weeks, 
cardiovascular diseases history, logarithm transformed triglyceride, logarithm 
transformed low-density lipoprotein cholesterol, prealbumin, logarithm 
transformed high-density lipoprotein cholesterol, logarithm transformed 
sensitive-reactive protein and logarithm transformed urinary albumin/creatinine 
ratio
Model 3: Model 2+ estimated glomerular filtration rate
ESKD end stage kidney disease, SD standard deviation
Serum 
uromodulin 
tertiles (ng/mL)
Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI)
ESKD events
 > 100.8 1.00 (Ref ) 1.00 (Ref ) 1.00 (Ref )
 > 52.7–100.8 3.70 (2.48, 5.54) 3.23 (2.15, 4.85) 1.36 (0.90, 2.06)
 ≤ 52.7 10.46 (7.20, 15.21) 7.47 (5.06, 11.03) 1.92 (1.26, 2.90)
 Per SD increase 0.26 (0.21, 0.32) 0.31 (0.25, 0.38) 0.69 (0.55, 0.86)
Cardiovascular events
 > 100.8 1.00 (Ref ) 1.00 (Ref ) 1.00 (Ref )
 > 52.7–100.8 1.37 (0.92, 2.04) 1.04 (0.70, 1.56) 0.80 (0.52, 1.22)
 ≤ 52.7 1.85 (1.27, 2.70) 1.24 (0.83, 1.86) 0.81 (0.51, 1.28)
 Per SD increase 0.71 (0.59, 0.87) 0.88 (0.72, 1.08) 1.14 (0.89, 1.45)
All‑cause mortality
 > 100.8 1.00 (Ref ) 1.00 (Ref ) 1.00 (Ref )
 > 52.7–100.8 1.63 (0.80, 3.29) 1.35 (0.65, 2.77) 1.04 (0.48, 2.23)
 ≤ 52.7 2.59 (1.34, 5.00) 1.94 (0.96, 3.94) 1.30 (0.58, 2.93)
 Per SD increase 0.63 (0.45, 0.89) 0.73 (0.51, 1.04) 0.92 (0.60, 1.41)
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kidney damage. With regard to the cardiovascular com-
plications, Leiherer et al. and Delgado et al. reported that 
serum uromodulin could predict the risk of cardiovas-
cular events and all-cause mortality among people with 
coronary disease [15, 16]. However, we did not observe 
similar associations in our study. The different eth-
nic background and a lower cardiovascular risk profile 
(younger age, lower levels of blood pressure and lower 
prevalence of diabetes mellitus) might be the reasons for 
such inconsistency.
There are some limitations of the current study. First, 
the cohort has a relatively short duration of follow-up 
and a limited number of cardiovascular events and death, 
which limited our power to investigate the association 
between the levels of uromodulin and cardiovascular 
disease. Furthermore, some laboratory tests for cardio-
vascular disease, including NT-proBNP, hs-Troponin 
and Galectin-binding protein, were not included in our 
study. Second, although most well-established risk fac-
tors of CKD progression were included in the multi-
variable regression models, the possibility of residual 
confounding still exists. Finally, considering the baseline 
characteristics of our study, these results will be primarily 
applicable to patients seen by nephrologists rather than 
the large population with CKD in the general population 
who have lower levels of proteinuria and older age.
Conclusions
This study represents the first prospective cohort study 
with a large sample size investigating the association 
between serum uromodulin and outcomes in CKD popu-
lation. Serum uromodulin levels are independently asso-
ciated with incident ESKD.
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